Komori
Dividends4512WAKAMOTO PHARMACEUTICAL CO.,LTD.Pharmaceuticals

Notice Concerning Revision of Dividend Forecast

The year-end dividend forecast for the fiscal year ending March 2024 was set at ¥3 per share, replacing the previous forecast of undecided. The total annual dividend will be ¥3 per share.

Worth reading
51Recurring
Scored from 3 of 5 sections
Direction
Neutral
Direction inferred from the company’s description.
Scale
3
¥ per share
Wording
Conditional
How definitive the wording is.

Dividend per share

Fiscal year ending March 2024
3YenDividend per share for this transactionPrior-year result ¥3, change ¥0
Previous-period resultsCurrent

Each vertical step represents one dividend payment, and the total height of the accumulated steps represents the annual dividend for the period. For periods showing only the annual amount, the payment breakdown is not provided, so only the end point is plotted.

Whether Submission to the General Meeting of Shareholders Is RequiredScheduled to be submitted to the General Meeting of Shareholders
Dividend policy

安定的な配当を基本としながら財務体質の強化を図りつつ、製造設備・技術の強化、研究開発、営業活動の強化のための投資に積極的に資金を充当し企業価値の増大を目指す。

Dividend per share
ItemDetails
Dividend per shareNot disclosed → 3.00 yen
Total Annual DividendsNot disclosed → 3.00 yen
Previous-period results (per share)Interim 0.00 yen / End of period 3.00 yen / Annual 3.00 yen
Dividend policy安定的な配当を基本としながら財務体質の強化を図りつつ、製造設備・技術の強化、研究開発、営業活動の強化のための投資に積極的に資金を充当し企業価値の増大を目指す。
Whether Submission to the General Meeting of Shareholders Is RequiredScheduled to be submitted to the General Meeting of Shareholders
Fiscal Period CoveredFiscal year ending March 2024
Items this document does not state (6)
Total dividendsRecord dateEffective dateSource of dividendsBreakdown of Regular, Commemorative and Special DividendsPayout ratio

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

業績が不透明だったため期末配当予想を未定としていたが、当期の業績見通しを総合的に判断した結果、配当を決定した。配当は安定的な配当を基本とし、財務体質の強化や製造設備・技術、研究開発、営業活動への投資も進める方針としている。

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Notice Concerning Revision of Dividend Forecast | WAKAMOTO PHARMACEUTICAL CO.,LTD. (4512) timely disclosure | Komori